Results 221 to 230 of about 156,654 (268)

ACTIVE IMMUNOTHERAPY FOR ACUTE LYMPHOBLASTIC LEUKÆMIA

The Lancet, 1969
Abstract Active immunotherapy (with B.C.G. and/or vaccination from a pool of allogeneic leukaemic " lymphoblasts " pretreated with formalin or irradiated in vitro) has been given to patients with acute lymphoblastic leukaemia who had previously been treated by chemotherapy, to induce a remission, and by complementary chemotherapy designed to reduce ...
G, Mathé, J L, Amiel, L, Schwarzenberg, M, Schneider, A, Cattan, J R, Schlumberger, M, Hayat, F, De Vassal   +7 more
openaire   +2 more sources

ACTIVE SPECIFIC IMMUNOTHERAPY FOR OVARIAN CANCER

The Lancet, 1976
Ten patients with advanced or recurrent ovarian cancer were treated with a combination of chemotherapy and active specific immunotherapy after tumour stasis had been induced. They were inoculated with irradiated allogeneic cryopreserved tumour cells and B.C.G. once monthly in addition to receiving conventional chemotherapy.
C N, Hudson, J E, McHardy, O M, Curling, P E, English, L, Levin, T A, Poulton, M, Crowther, M, Leighton   +7 more
openaire   +2 more sources

Active Specific Immunotherapy Against Adenocarcinomas

Cancer Investigation, 1994
(1994). Active Specific Immunotherapy Against Adenocarcinomas. Cancer Investigation: Vol. 12, No. 1, pp. 46-56.
G D, MacLean, M A, Reddish, M B, Bowen-Yacyshyn, S, Poppema, B M, Longenecker   +4 more
openaire   +2 more sources

Active immunotherapy in follicular lymphoma

Seminars in Cancer Biology, 2003
The antigen receptors expressed by follicular lymphomas represent tumor-specific antigens ("idiotypes"). In murine models, vaccination with tumor-derived idiotype in a variety of formulations can induce protective lymphoma-specific immunity. Phase II clinical trials in follicular lymphoma have also demonstrated idiotype-specific immune responses ...
openaire   +3 more sources

Active Immunotherapy by B.C.G.

1971
Immunotherapy is a new method of killing malignant cells in the treatment of cancer. It is well known, from the rejection of incompatible grafts, that membrane antigens can excite an immune reaction capable of killing cells carrying these antigens. It is also known that these immune reactions can sometimes fail to kill the cells that have raised the ...
G. Mathe, J. L. Amiel, L. Schwarzenberg, M. Schneider   +3 more
openaire   +1 more source

Active specific immunotherapy for colorectal cancer

Expert Review of Anticancer Therapy, 2003
With advances in molecular biology and the identification of tumor-associated antigens, a number of new strategies have been developed in an attempt to overcome the limits of chemotherapy and to aid in the fight to cure patients of metastatic and micrometastatic colorectal carcinomas.
Adrian A, Indar, Charles A, Maxwell-Armstrong   +1 more
openaire   +2 more sources

Venom immunotherapy induces monocyte activation

Clinical & Experimental Allergy, 2001
Background Venom immunotherapy (VIT) is an efficient treatment of hymenoptera venom allergy. The mechanism of VIT is based on the induction of tolerance of allergen‐specific Th2 cells. The mechanisms of this T cell modulation are unknown, and could depend on cytokines produced by other cell types such as interleukin (IL)‐12, tumour necrosis factor (TNF)
A, Magnan, V, Marin, L, Mély, J, Birnbaum, S, Romanet, P, Bongrand, D, Vervloet   +6 more
openaire   +2 more sources

Active Specific Immunotherapy in Ovarian Cancer

1979
The rationale of any programme of active specific immunotherapy depends on the demonstration of appropriate tumour-directed, cell-mediated immune responses, and agents designed to manipulate these immunological responses must be shown to have some therapeutic effect.
M E, Crowther, L, Levin, T A, Poulton, M J, Saffrey, O M, Curling, C N, Hudson   +5 more
openaire   +2 more sources

Active specific immunotherapy in malignant melanoma

Seminars in Surgical Oncology, 1989
AbstractWe have recently initiated clinical trials of active specific immunotherapy evaluating a new polyvalent melanoma cell vaccine in patients with high‐risk and/or recurrent melanoma. The vaccine has been administered alone, or in combination with low‐dose cyclophosphamide, as an immunomodulator of suppressor cells. Cyclophosphamide is effective in
D L, Morton, L J, Foshag, J A, Nizze, R K, Gupta, E, Famatiga, D S, Hoon, R F, Irie   +6 more
openaire   +2 more sources

Active and passive immunotherapy: vaccines and antibodies

BJU International, 2007
Contains fulltext : 52701.pdf (Publisher’s version ) (Closed access)
Oosterwijk, E., Divgi, C.R., Bander, N.H.   +2 more
openaire   +3 more sources